Experiences with

Arzerra

In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis

Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (Arzerra) while producing rapid and durable responses in heavily pretreated patients.

She is now trying Arzerra. Wondering if anyone has had Arzerra as a treatment for this as what I read shows it as a treatment for CLL.

Just wondered if anyone else had had Arzerra for lymphoma rather than CLL.

In DUO, duvelisib reduced the risk of disease progression or death by 60% versus ofatumumab (Arzerra) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.

This was 3.4 months longer than in patients treated with Arzerra. Source: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2298616

Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."

[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus ofatumumab (Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a

These include rituximab (Rituxan), ofatuzumab (Arzerra), and obinituzumab (Gazyva). Among other topics, I discuss the difference between type I and type II monoclonal antibodies.

Two buses arrive at the same time on the same day making new treatments available to NHS England & Wales CLL patients Technology appraisal guidance [TA344] Published date: June 2015 You can access full guidance details on the NICE website here: http://www.nice.org.uk/guidance/ta344 [i]Ofatumumab (Arzerra

Ofatumumab (Arzerra) [i]Advice following a full submission assessed under the orphan process ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.

[/i] http://www.pharmacydaily.com.au/news/arzerra-pbs-listed/41548 This news even made the National 7 News, which gave a good overview of CLL and included a brief interview with Dr Con Tam. Neil

GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients

Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.

Source http://www.gsk.com/media/press-releases/2013/fda-grants-gsk-and-genmabs-arzerra---ofatumumab--breakthrough-th.html

temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com

ReleaseID=760980 Note: ARZERRA is not approved for the treatment of untreated CLL anywhere in the world. It is approved for use in fludarabine refractory CLL, in the US and EU

"We are pleased that patients in Japan will now have access to Arzerra. Japan is another important market for Arzerra and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.